Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Drug reduces acute GVHD in unrelated HSCTs

    ... who did not receive vorinostat (P = .026). Day 30 plasma levels of inflammatory cytokines interleukin (IL)-6 and IL-10 were ...

    Article last updated 02/27/2017 - 1:45pm.

  2. Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis

    ... gastrointestinal bleeding, hematuria, and elevated plasma lactate dehydrogenase ; he started eculizumab therapy ...

    Research Article last updated 11/02/2016 - 2:49pm.

  3. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment

    ... C5 polymorphisms and evaluated for free eculizumab in plasma . We report that 10 patients (83%) present parameters suggesting ... CR1-L allele results in abnormally decreased levels of C3 in plasma that could, potentially, increase their susceptibility to bacterial ...

    Research Article last updated 10/06/2016 - 8:50am.

  4. The prognostic value of serum c-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes

    ... were centrally quantified by ELISA from cryopreserved plasma whereas each center provided pre-transplant albumin. In multivariate ...

    Research Article last updated 10/06/2016 - 11:27am.

  5. Clone of Patients

    Learn About Your Disease Once the initial shock of a bone marrow failure diagnosis wears off, the best thing to do is lea...

    Page last updated 03/14/2016 - 6:05pm.

  6. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... in a phase 1 dose-finding study. AZA has a short plasma half-life and DNA incorporation is S-phase-restricted; extending ...

    Research Article last updated 12/09/2015 - 8:56am.

  7. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

    ... eculizumab was associated with significant decreases in plasma markers of coagulation activation (F1+2, P=0.012, and D-dimers, ... P=0.0002). Eculizumab treatment also significantly reduced plasma markers of endothelial cell activation (t-PA, P=0.0005, sVCAM-1, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Complement Blockade with a C1 Esterase Inhibitor in Paroxysmal Nocturnal Hemoglobinuria

    ... C1 esterase inhibitor (C1INH) is an endogenous human plasma protein that has broad inhibitory activity in the complement ... pathway. In this study, we show that commercially available plasma derived C1INH prevents lysis induced by the alternative complement ...

    Research Article last updated 08/04/2014 - 8:13am.

  9. In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia

    ... Rabbit antithymocyte globulin was detectable in plasma for longer periods than horse antithymocyte globulin; rabbit antithymocyte globulin in plasma retained functional capacity to bind to lymphocytes for up to one ...

    Research Article last updated 06/19/2014 - 12:42pm.

  10. Self-injected PNH therapy on the horizon

    ... Across four patient groups, ACH-4471 achieved peak plasma concentrations between one and 2.5 hours after oral dosing. Up to ...

    Article last updated 07/07/2016 - 9:40am.